Search

MSK researchers and collaborators have developed a new type of CAR T cell designed to attack a cell surface protein called uPAR — allowing them to target both tumors and cancer-supporting cells in the tumor microenvironment.

… Monday, March 30, 2026 Chimeric antigen receptor T-cell therapy — CAR T for short — has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two main reasons: tumor cells often don’t share one consistent surface target

Atefeh “Atti” Riazi, Senior Vice President and Chief Information Officer of Memorial Sloan Kettering Cancer Center (MSK) has been selected as a recipient of the 2022 Health Information and Management System Society (HIMSS) Most Influential Women in Health IT Awards. 

… Monday, March 14, 2022 Atefeh “Atti” Riazi, Senior Vice President and Chief Information Officer of Memorial Sloan Kettering Cancer Center (MSK) has been selected as a recipient of the 2022 Health Information and Management System Society (HIMSS) Most Influential Women in Health IT Awards .  The award

Memorial Sloan Kettering attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice.

… Wednesday, November 25, 2020 VIDEO | 03:09 2020 MSK Nurses Magnet Recognition Video Details On November 23, 2020, Memorial Sloan Kettering (MSK) attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice. The American Nurses Credentialing

MSK’s Convocation and the Gerstner Sloan Kettering Graduate School of Biomedical Sciences Commencement celebrate the achievements of young scientists.

… Wednesday, June 10, 2015 Ruth Anne Franklin (left), Ming Li, Myoungjoo Kim Graduates Ruth Anne Franklin (left) and Myoungjoo Kim with their mentor, immunologist Ming Li 2015 graduates Graduates of GSK and a joint program between Weill Cornell Medical College and the Sloan Kettering Institute with their

Memorial Sloan Kettering has named three winners of this year’s Paul Marks Prize for Cancer Research, an award that recognizes promising investigators.

… Friday, November 8, 2019 Summary The Paul Marks Prize for Cancer Research, first awarded in 2001, recognizes promising scientists who have made important contributions to the study of cancer. Memorial Sloan Kettering has named three investigators as the recipients of this year’s Paul Marks Prize for

Learn how CAR T cell therapy and the expertise of MSK gave Guillaume Arnould another option for treating multiple myeloma, after other therapies failed.

… Tuesday, November 7, 2023 Shortly after finding out his wife was pregnant with their son, Guillaume Arnould got terrible news about his own health: He had multiple myeloma , a rare blood cancer. He was just 33 years old. The following six years were a grueling succession of stem cell transplants stem

Meet Matthew Solowsky, a Navy veteran and Senior Research Technician in the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center.

… Thursday, November 11, 2021 Matthew Solowsky says he has always been driven and focused. “The hardships from my childhood made me want to rise above circumstances that were outside of myself,” says Mr. Solowsky, who is now a Senior Research Technician in the Center for Molecular Oncology (CMO)  at Memorial

Bispecific antibodies bind to two antigens or two parts of the same antigen at the same time. The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with relapsed or refractory follicular lymphoma and glofitamab (glofit) for patients with relapsed or refractory diffuse B cell lymphoma (DLBCL) or large B cell lymphoma (LBCL) treated with two or more prior lines of therapy.

… Monday, December 11, 2023 Bispecific antibodies bind to two antigens or two parts of the same antigen at the same time. The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with relapsed or refractory follicular lymphoma

Meet author Amy Blumenfeld, whose experience as a pediatric patient at Memorial Sloan Kettering inspired her first novel, The Cast.

… Friday, November 16, 2018 Summary In 1989, 15-year-old Amy Blumenfeld was treated for Hodgkin lymphoma at Memorial Sloan Kettering. Her first novel, The Cast, is loosely based on her experience. In the late 1980s, when she was 13, Amy Blumenfeld was diagnosed with Hodgkin lymphoma. She had 11 months

New MSK research provides insights into how BRCA2 promotes genomic integrity; illuminates how embryonic cells can develop without key amino acids; explores how the microbiome bounces back after antibiotic treatment; and investigates acquired resistance to immunotherapy in non-small cell lung cancer.

… Monday, January 29, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) provides insights into how BRCA2 promotes genomic integrity; illuminates how embryonic cells can develop without key amino acids; explores how the microbiome bounces back after antibiotic treatment; and investigates